OneSource Specialty Pharma Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9sz8d9g5y7ibhi11zypa52ec.pdf

Key Takeaways


Semaglutide: From Pipeline to Commercial Engine

Neeraj Sharma: "Specifically, on Semaglutide, you know many of your questions would be around that, so specifically here, we have moved in this quarter from pipeline to real proof."

Capacity Build-Out: The $400 Million Foundation

Neeraj Sharma: "right now the biggest challenge actually for the customers is access to capacity. And for them to secure this access, customers have done capacity reservation with us. And that capacity reservation includes blocking capacity and submitting to pick up that capacity both by paying upfront fee as well as take-or-pay kind of contract."

Biologics: The FY28 Growth Wedge


Financial Health & the Scheme Pause

Arun Kumar: "We didn't get that same comfort this time, although we would have got through majority without difficulties, and we decided to pause this for some more time and come back and discuss this further."

Base Business & Compliance Moat


Guidance & Commitments

CommitmentSpecificsTimeline
Organic revenue target$400 million with ~40% EBITDA marginsFY28
Second DDC line commercializationLine undergoing qualification, available for commercial productionQ2 FY27 (next quarter)
Third DDC line installationThird line added, three lines installed totalBy end of FY27
Sequential revenue and EBITDA improvementQuarter-on-quarter growth built on new capacity availabilityThroughout FY27
Working capital normalizationElevated inventory to normalizeDuring FY27
ROCE targetBuild toward 50%+Medium term
Biologics meaningful contributionAgreements signed, revenue contribution visibleFY27 and FY28
Biologics commercial manufacturingCommercial production beginsBeyond FY28, from FY29
Soft gelatin capacity fully utilizedNo real capacity available beyond currentEnd of CY26 or CY27
Scheme re-evaluationRevisit Steriscience/Brooks consolidationIn roughly two years

Key Metrics

MetricQ4 FY26
Revenue₹428.2 cr, +47% QoQ
Full-year revenue₹1,421.6 cr, -2% YoY
EBITDA₹91.9 cr, more than 5x QoQ
EBITDA margin expansion1,550 bps QoQ
Full-year EBITDA decline~35% YoY, due to delayed Semaglutide approvals
Adjusted PAT~₹39 cr, versus a loss in Q3
Full-year adjusted PAT₹73.9 cr
EPS (fully diluted)₹3.4
Full-year EPS₹6.5
Cost of borrowingBelow 9%, 210 bps lower than prior year
FY28 organic revenue guidanceUS$400 million, with ~40% EBITDA margins, reiterated
DDC capacity expansion capexUS$100 million
DDC lines installed by end of FY273 lines, with 675 odd sterile manufacturing days available
Biologics funnel expansion~4x versus previous year
Regulatory and customer audits completed in FY2649